<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02233322</url>
  </required_header>
  <id_info>
    <org_study_id>IRON/ADHR</org_study_id>
    <nct_id>NCT02233322</nct_id>
  </id_info>
  <brief_title>Iron Therapy for Autosomal Dominant Hypophosphatemic Rickets: A Pilot Project.</brief_title>
  <official_title>Iron Therapy for Autosomal Dominant Hypophosphatemic Rickets: A Pilot</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indiana University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Indiana University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to gain a better understanding of the effect of iron on
      fibroblast growth factor 23 (FGF23) in the inherited disorder, autosomal dominant
      hypophosphatemic rickets (ADHR). ADHR is an inherited disorder in which the body makes too
      much FGF 23 and causes low blood phosphorus levels and bone problems such as rickets (bowed
      legs in children) or bone pain and weakness in adults. This study is to test whether or not
      giving iron helps correct the high FGF23 and there by correcting the phosphate problem.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Iron will be provided in an open label treatment to all enrolled subjects. Iron levels will
      be monitored in blood and doses adjusted with the target of getting the iron levels to or a
      little above 100 mcg/dl.

      The study will look to see if there is a decrease of FGF23 level. It will also look at how
      long does it take to decrease the level of FGF 23 and how long it takes for the serum and
      urine phosphate to normalize.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2014</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Does increasing serum iron concentrations above 100 mcg/dl in patients with ADHR result in a decrease in intact FGF23.</measure>
    <time_frame>FGF23 will be measured at 1, 2, 3, 6, 9, and 12 months</time_frame>
    <description>Perform a pilot study in ADHR patients with low serum iron concentrations (defined below) to determine if increasing serum iron concentrations above 100 mcg/dl results in a decrease in intact FGF23 (primary endpoint) and C-terminal FGF23 concentrations by at least 20% and normalizes serum phosphorus and TMP/GFR (tubular maximum phosphate reabsorption/ glomerular filtration rate) within 6 months of attaining goal iron concentrations.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">8</enrollment>
  <condition>Autosomal Dominant Hypophosphatemic Rickets</condition>
  <arm_group>
    <arm_group_label>iron supplements</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>all subjects will receive iron supplementation based on iron levels in blood</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Iron</intervention_name>
    <description>All subjects will receive iron supplementation based on iron levels in the blood</description>
    <arm_group_label>iron supplements</arm_group_label>
    <other_name>Ferrous Sulfate</other_name>
    <other_name>Ferrous Gluconate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  FGF Mutation in either Arginine 176 or arginine 179

          -  able and willing to provide consent or have a parent that is able/willing to consent,
             if a minor

          -  either serum iron &lt;50mcg/dl (regardless of phosphate or intact FGF23 concentration);
             or iron between 500 and 100mcg/dl with serum phosphorus value below 3.0mg/dl for
             adults or less than or equal to 0.5 mg/dl the lower limit of normal for age in
             children and intact FGF23 about 30pg/ml

          -  age &gt;2 years

          -  May be receiving treatment with phosphate and calcitriol, but must be willing to
             undergo dose adjustments by the investigators if iron resolves the phosphate wasting
             defect.

        Exclusion Criteria:

          -  malignancy within the last 5 years, except treated squamous or basal cell skin
             carcinoma

          -  terminal illness/hospice.

          -  severe end-organ disease, e.g. cardiovascular, pulmonary, etc, which may limit ability
             to complete study.

        estimated GFR &lt;45ml/min/1.73m2, calculated using MDRD formula for adults or modified
        Schwartz equation for children

          -  pregnancy or plan on becoming pregnant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Months</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Econs, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marian D Hart, BSN, RN</last_name>
    <phone>317-948-8346</phone>
    <email>marihart@iu.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Connie Sullivan, BSN, RN</last_name>
    <phone>317-944-8431</phone>
    <email>csulliv1@iu.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Indiana University School of Medicine</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marian D Hart, B.S.N., R.N.</last_name>
      <phone>317-948-8346</phone>
      <email>marihart@iu.edu</email>
    </contact>
    <contact_backup>
      <last_name>Connie Sullivan, B.S.N., R.N</last_name>
      <phone>317-944-8431</phone>
      <email>csulliv1@iu.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Michael Econs, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Erik A Imel, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rakesh Mehta, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>White KE, Carn G, Lorenz-Depiereux B, Benet-Pages A, Strom TM, Econs MJ. Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23. Kidney Int. 2001 Dec;60(6):2079-86.</citation>
    <PMID>11737582</PMID>
  </reference>
  <reference>
    <citation>Imel EA, Hui SL, Econs MJ. FGF23 concentrations vary with disease status in autosomal dominant hypophosphatemic rickets. J Bone Miner Res. 2007 Apr;22(4):520-6.</citation>
    <PMID>17227222</PMID>
  </reference>
  <reference>
    <citation>Imel EA, Peacock M, Gray AK, Padgett LR, Hui SL, Econs MJ. Iron modifies plasma FGF23 differently in autosomal dominant hypophosphatemic rickets and healthy humans. J Clin Endocrinol Metab. 2011 Nov;96(11):3541-9. doi: 10.1210/jc.2011-1239. Epub 2011 Aug 31.</citation>
    <PMID>21880793</PMID>
  </reference>
  <reference>
    <citation>Farrow EG, Yu X, Summers LJ, Davis SI, Fleet JC, Allen MR, Robling AG, Stayrook KR, Jideonwo V, Magers MJ, Garringer HJ, Vidal R, Chan RJ, Goodwin CB, Hui SL, Peacock M, White KE. Iron deficiency drives an autosomal dominant hypophosphatemic rickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in mice. Proc Natl Acad Sci U S A. 2011 Nov 15;108(46):E1146-55. doi: 10.1073/pnas.1110905108. Epub 2011 Oct 17.</citation>
    <PMID>22006328</PMID>
  </reference>
  <reference>
    <citation>Econs MJ, McEnery PT. Autosomal dominant hypophosphatemic rickets/osteomalacia: clinical characterization of a novel renal phosphate-wasting disorder. J Clin Endocrinol Metab. 1997 Feb;82(2):674-81.</citation>
    <PMID>9024275</PMID>
  </reference>
  <reference>
    <citation>Schouten BJ, Doogue MP, Soule SG, Hunt PJ. Iron polymaltose-induced FGF23 elevation complicated by hypophosphataemic osteomalacia. Ann Clin Biochem. 2009 Mar;46(Pt 2):167-9. doi: 10.1258/acb.2008.008151. Epub 2009 Jan 16.</citation>
    <PMID>19151167</PMID>
  </reference>
  <reference>
    <citation>Schouten BJ, Hunt PJ, Livesey JH, Frampton CM, Soule SG. FGF23 elevation and hypophosphatemia after intravenous iron polymaltose: a prospective study. J Clin Endocrinol Metab. 2009 Jul;94(7):2332-7. doi: 10.1210/jc.2008-2396. Epub 2009 Apr 14.</citation>
    <PMID>19366850</PMID>
  </reference>
  <reference>
    <citation>Shimizu Y, Tada Y, Yamauchi M, Okamoto T, Suzuki H, Ito N, Fukumoto S, Sugimoto T, Fujita T. Hypophosphatemia induced by intravenous administration of saccharated ferric oxide: another form of FGF23-related hypophosphatemia. Bone. 2009 Oct;45(4):814-6. doi: 10.1016/j.bone.2009.06.017. Epub 2009 Jun 23.</citation>
    <PMID>19555782</PMID>
  </reference>
  <reference>
    <citation>Bianchine JW, Stambler AA, Harrison HE. Familial hypophosphatemic rickets showing autosomal dominant inheritance. Birth Defects Orig Artic Ser. 1971 May;7(6):287-95.</citation>
    <PMID>5173181</PMID>
  </reference>
  <reference>
    <citation>Econs MJ, McEnery PT, Lennon F, Speer MC. Autosomal dominant hypophosphatemic rickets is linked to chromosome 12p13. J Clin Invest. 1997 Dec 1;100(11):2653-7.</citation>
    <PMID>9389727</PMID>
  </reference>
  <reference>
    <citation>Schwartz GJ, Mu√±oz A, Schneider MF, Mak RH, Kaskel F, Warady BA, Furth SL. New equations to estimate GFR in children with CKD. J Am Soc Nephrol. 2009 Mar;20(3):629-37. doi: 10.1681/ASN.2008030287. Epub 2009 Jan 21.</citation>
    <PMID>19158356</PMID>
  </reference>
  <reference>
    <citation>Walton RJ, Bijvoet OL. Nomogram for derivation of renal threshold phosphate concentration. Lancet. 1975 Aug 16;2(7929):309-10.</citation>
    <PMID>50513</PMID>
  </reference>
  <reference>
    <citation>Ichikawa S, Imel EA, Kreiter ML, Yu X, Mackenzie DS, Sorenson AH, Goetz R, Mohammadi M, White KE, Econs MJ. A homozygous missense mutation in human KLOTHO causes severe tumoral calcinosis. J Clin Invest. 2007 Sep;117(9):2684-91.</citation>
    <PMID>17710231</PMID>
  </reference>
  <reference>
    <citation>Imel EA, DiMeglio LA, Hui SL, Carpenter TO, Econs MJ. Treatment of X-linked hypophosphatemia with calcitriol and phosphate increases circulating fibroblast growth factor 23 concentrations. J Clin Endocrinol Metab. 2010 Apr;95(4):1846-50. doi: 10.1210/jc.2009-1671. Epub 2010 Feb 15.</citation>
    <PMID>20157195</PMID>
  </reference>
  <reference>
    <citation>Imel EA, Peacock M, Pitukcheewanont P, Heller HJ, Ward LM, Shulman D, Kassem M, Rackoff P, Zimering M, Dalkin A, Drobny E, Colussi G, Shaker JL, Hoogendoorn EH, Hui SL, Econs MJ. Sensitivity of fibroblast growth factor 23 measurements in tumor-induced osteomalacia. J Clin Endocrinol Metab. 2006 Jun;91(6):2055-61. Epub 2006 Mar 21.</citation>
    <PMID>16551733</PMID>
  </reference>
  <reference>
    <citation>Sabbagh, Y., Tenenhouse HS, Econs, MJ, Mendelian Hypophosphatemias, in The Metabolic and Molecular Basis of Inherited Disease, C.R.S.e. al, Editor. 2008, McGraw-Hill: New York.</citation>
  </reference>
  <reference>
    <citation>White, K.E. and M.J. Econs, Fibroblast growth factor-23 (FGF23), in Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. 2013, Wiley-Blackwell. p. 188-194.</citation>
  </reference>
  <reference>
    <citation>The ADHR Consortium: Group 1:White, K.E., E.W., O'Riordan JLH, Speer MC, Econs MJ. Group 2: Lorenz-Depiereux B, Grabowski M, Meitinger T, Strom TM., Autosomal dominat hypophospataemic rickets is associated with mutations in FGF23. Nat Genet, 2000. 26(3): p. 345-8.</citation>
  </reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 27, 2014</study_first_submitted>
  <study_first_submitted_qc>September 2, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 8, 2014</study_first_posted>
  <last_update_submitted>August 9, 2017</last_update_submitted>
  <last_update_submitted_qc>August 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Indiana University</investigator_affiliation>
    <investigator_full_name>Michael Econs</investigator_full_name>
    <investigator_title>Professor of Endocrinology and Metabolism</investigator_title>
  </responsible_party>
  <keyword>ADHR</keyword>
  <keyword>Rickets</keyword>
  <keyword>Hypophosphatemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rickets</mesh_term>
    <mesh_term>Rickets, Hypophosphatemic</mesh_term>
    <mesh_term>Familial Hypophosphatemic Rickets</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Iron</mesh_term>
    <mesh_term>Ferrous gluconate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

